Estimaciones de analistas de Wall Street para Halozyme Therapeutics, Inc. (HALO): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-02 | $2.25 | ||
| 2026-08-06 | $2.28 | $1.79 | +27.4% |
| 2026-05-11 | $1.60 | $1.55 | +3.2% |
| 2026-02-17 | $-0.24 | $2.15 | -111.2% |
| 2025-11-03 | $1.72 | $1.63 | +5.5% |
| 2025-08-05 | $1.54 | $1.23 | +25.2% |
| 2025-05-06 | $1.11 | $0.95 | +16.8% |
| 2025-02-18 | $1.26 | $1.17 | +7.7% |
Ratios de valoración
| Ratio P/E | 30.18 |
| Precio / Valor contable | 86.81 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $146.7M | $316.6M | $151.9M | $196.0M | $267.6M | $443.3M | $660.1M | $829.3M | $1.02B | $1.40B |
| Coste de Ventas | $33.2M | $31.2M | $10.1M | $45.5M | $43.4M | $81.4M | $139.3M | $192.4M | $159.4M | $305.4M |
| Beneficio Bruto | $113.5M | $285.5M | $141.7M | $150.4M | $224.2M | $361.9M | $520.8M | $636.9M | $855.9M | $1.09B |
| I+D | $150.8M | $150.6M | $150.3M | $140.8M | $34.2M | $35.7M | $66.6M | $76.4M | $79.0M | $81.5M |
| Generales y Administrativos | $45.9M | $53.8M | $60.8M | $77.3M | $45.7M | $50.3M | $143.5M | $149.2M | $154.3M | $193.4M |
| Gastos Operativos | $196.7M | $204.5M | $211.1M | $218.1M | $80.0M | $86.0M | $253.3M | $299.3M | $304.4M | $274.9M |
| Beneficio Operativo | -$83.2M | $81.0M | -$69.3M | -$67.6M | $144.3M | $275.9M | $267.5M | $337.6M | $551.5M | $816.3M |
| EBITDA | -$79.5M | $83.2M | -$69.3M | -$56.6M | $153.0M | $259.0M | $315.5M | $451.9M | $656.5M | $573.1M |
| Gastos por Intereses | $20.0M | $22.0M | $18.0M | $11.6M | $20.4M | $7.5M | $16.9M | $18.8M | $18.1M | $18.1M |
| Beneficio Antes de Impuestos | -$101.9M | $61.6M | -$79.8M | -$72.3M | $129.3M | $248.5M | $248.9M | $348.3M | $557.1M | $466.9M |
| Impuestos | $1.2M | -$1.4M | $537000 | -$11000 | $217000 | -$154.2M | $46.8M | $66.7M | $113.0M | $150.0M |
| Beneficio Neto | -$103.0M | $63.0M | -$80.3M | -$72.2M | $129.1M | $402.7M | $202.1M | $281.6M | $444.1M | $316.9M |
| BPA | $-0.81 | $0.46 | $-0.56 | $-0.50 | $0.95 | $2.86 | $1.48 | $2.13 | $3.50 | $2.64 |
| BPA Diluido | $-0.81 | $0.45 | $-0.56 | $-0.50 | $0.91 | $2.74 | $1.44 | $2.10 | $3.43 | $2.56 |
| Acciones en Circulación (Diluidas) | $128.0M | $139.1M | $143.6M | $144.3M | $141.5M | $146.8M | $140.6M | $134.2M | $129.4M | $123.9M |
Precio
| Precio | $108.44 |
| Capitalización | $12.9B |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: ABVX · ATR · CAI · CORT · CYTK · GRFS · HSIC
Explorar sector: Healthcare · Biotechnology
Más secciones de HALO: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones